Inside Deep Principle: The AI That Runs Its Own Chemistry Experiments to Discover New Materials

MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide

MIRA Pharmaceuticals Announces Its Data From Exploratory Pilot Of SKNY-1 Shows Reductions In Body Weight, Fat Mass

MIRA Pharmaceuticals Announces Initial Proof-Of-Concept Results From Pilot Study Of SKNY-1 For Obesity And Metabolic Disorders In A Diet-Induced Obesity Mouse Model; Study Demonstrated Statistically Significant Reductions In Body Weight And Fat Mass Following Oral Administration Of SKNY-1 Compared With Vehicle-Treated Controls

MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study

MIRA Pharma Reports 21-Day Preclinical Proof-Of-Concept Study Showing That Once-Daily Oral MIRA-55 Significantly Reduced Mechanical And Thermal Pain Hypersensitivity; Results Back MIRA-55's Progress Toward IND Filing

Modera Launches AI-Powered Platform Mira to Support Tailored Financial Advice for Clients

A drug candidate is moving toward its first patient test for nerve pain caused by chemotherapy. MIRA targets Q1 2027.

Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

MIRA Forecast — Price Target — Prediction for 2027

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy